Pharma Q3 Preview: Amgen, Allergan, Pfizer, GSK And Sanofi
Executive Summary
Pfizer CEO Ian Read will preside over his last sales and earnings call as the big pharma's chief executive, while for GlaxoSmithKline, uncertainty lingers over the timing of a generic Advair. Amgen will have its second opportunity to talk to investors about its 60% Repatha price cut, while answering questions about Aimovig strategy and Neulasta biosimilars. And other topics to watch in the next earnings calls...
You may also be interested in...
Part B's Foreign Price Bench-marking Will Only Hurt Bad Negotiators, HHS's Azar Argues
President Trump touts CMS proposal that would peg Part B prices to an international index in the hopes of lowering US costs; industry calls it foreign price controls and warns it will hinder access.
Amgen Drops Repatha List Price 60% To Cut Medicare Co-Pays And Boost Use
Company says 75% of Medicare Part D patients who aren't eligible for low income subsidies abandon the PCSK9 inhibitor at the pharmacy counter due to $370 co-pay, which may now range from $25-$150 per dose.
Dupixent Approved For Severe Asthma With Broader Label Than Other Biologics
The US FDA cleared Sanofi/Regeneron's IL-4/IL-13 inhibitor for moderate-to-severe asthma in patients with an eosinophilic phenotype or with oral corticosteroid-dependent asthma, a broader label than AstraZeneca's Fasenra, GSK's Nucala and Teva's Cinqair.